Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Next Big Score !


Johnny881
4 stars

7462 Reads | 62 Comments | 1 People call this a favourite

Over $14 billion spent on migranes annually in the US and Nupathe has proprietary patch delivery system that will target a chunk of this huge pie. PDUFA date set at January 17, which means we should see some steady appreciation in stock price til then regardless of what the eventual FDA decision is. A yes vote will undoubtedly have a huge impact on the small market cap and tight float. A great biotech to keep your eye on as the PDUFA date is now less than 2 months away. www.nupathe.com stock symbol :PATH on Nasdaq


  • Oil Reserves & Drilling 6 Wells


    48 Reads | 3 Comments | February 27, 2012

    Undervalued and more value to be added. Drilling of 6 wells in middle east to start soon! www.stockhouse.com/financialtools/sn_newsreleases.aspx?qm_symbol=v.mnh&newsid=8426130 www.stockhouse.com/financialtools/sn_newsreleases.aspx?qm_symbol=v.mnh&newsid=8433004 v.MNH


  • CORT Blockbuster Drug in the Making !


    58 Reads | 0 Comments | February 19, 2012

      FDA approval of Korlym for Cushing's Syndrome this past Friday, is fantastic news but is really just the tip of the iceberg.    Consider that Corcept is currently recruiting for phase 3 clinical trials of Korlym for Psychotic Depression. Success here could very well launch Korlym into the elite blockbuster drug status hauling in more than $1 billion in annual revenue....


  • CORT Gets FDA Approval !


    52 Reads | 2 Comments | February 18, 2012

    The FDA approval news came after market close on Friday. JMP Securities raised their price target to $9.00 for the stock. Here is the Reuters NR. Feb 17 (Reuters) - U.S. health regulators approved Corcept Therapeutics's Korlym, the first oral drug designed to treat a rare hormonal disorder called Cushing's syndrome. The U.S. Food and Drug Administration nod is for...



Blog Administrator

Johnny881
4 stars

120 Posts

Featured News Links